Immutep (IMMP) Net Cash Flow (2011 - 2024)
Immutep's (IMMP) quarterly Net Cash Flow came in at -$22.9 million in Q2 2024, up 2.89% YoY from -$22.3 million in Q3 2023, and up 2.89% on a QoQ basis from -$23.6 million in Q2 2023.
Immutep (IMMP) Net Cash Flow (2011 - 2024) Analysis & Trends
Immutep (IMMP) has 11 years of Net Cash Flow data on file, last reported at -$22.9 million in Q2 2024.
- Quarterly Net Cash Flow rose 2.89% year-over-year to -$22.9 million in Q2 2024, while the trailing twelve-month figure through Dec 2025 was -$22.9 million (up 50.73% YoY) and the FY2025 annual result came in at -$64.8 million, down 349.76% from the prior year.
- Net Cash Flow rose to -$22.9 million in Q2 2024, from -$23.6 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of -$7.1 million in Q2 2020 to a low of -$23.6 million in Q2 2023.
- A 3-year average of -$17.9 million and a median of -$22.9 million in 2024 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2020 — Net Cash Flow soared 33.65% — and 2024, when it gained 2.89%.
- Tracing IMMP's Net Cash Flow over 3 years: stood at -$7.1 million in 2020, then plunged by 232.62% to -$23.6 million in 2023, then increased by 2.89% to -$22.9 million in 2024.
- The last three Net Cash Flow figures came in at -$22.9 million (Q2 2024), -$23.6 million (Q2 2023), and -$7.1 million (Q2 2020), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.65 Bn | 130.80 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.94 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.84 Bn | 59.66 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.38 Bn | 52.25 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.94 Bn | 36.84 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.54 Bn | 28.23 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 27.72 Bn | 9.33 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 225.59 Mn |
| 10 | Immutep | 56.46 Mn | -8.63 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -22.95 Mn |
| Jun 30, 2024 | -22.95 Mn |
| Jun 30, 2023 | -23.63 Mn |
| Jun 30, 2023 | -23.63 Mn |
| Jun 30, 2020 | -7.10 Mn |
| Jun 30, 2020 | -7.10 Mn |
| Jun 30, 2019 | -10.71 Mn |
| Jun 30, 2019 | -10.71 Mn |
| Jun 30, 2017 | -6.39 Mn |
| Jun 30, 2017 | -6.39 Mn |
| Jun 30, 2016 | -8.29 Mn |
| Jun 30, 2016 | -8.29 Mn |
| Jun 30, 2015 | -6.05 Mn |
| Jun 30, 2015 | -6.05 Mn |
| Jun 30, 2014 | -13.27 Mn |
| Jun 30, 2014 | -13.27 Mn |
| Jun 30, 2013 | -15.93 Mn |
| Jun 30, 2013 | -15.93 Mn |
| Jun 30, 2012 | -19.32 Mn |
| Jun 30, 2012 | -19.32 Mn |